Sugi Predict

Sugi Predict / Compounds / SCHEMBL398615

SCHEMBL398615

SCHEMBL398615

NCCCP(=O)(O)CC1CCCCC1

nearest known ligand 0.72

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ GABBR2 O75899 3/20 0.47
▸ GABBR1 Q9UBS5 3/20 0.47
▸ GABRR1 P24046 1/20 0.46
▸ LMNA P02545 2/20 0.43
▸ BLM P54132 2/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ NFKB1 P19838 1/20 0.43
▸ PMP22 Q01453 1/20 0.43
▸ SIGMAR1 Q99720 1/20 0.42
▸ CYP1A2 P05177 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ THPO P40225 1/20 0.41
▸ METAP1 P53582 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6361016 0.90 GABBR2 (0.52) GABBR2GABBR1GABRR1LMNABLM
SCHEMBL5093197 0.85 CA12 (0.37) GABBR2GABBR1CYP3A4SIGMAR1CYP1A2
SCHEMBL5087334 0.83 CA12 (0.38) CYP3A4CYP1A2METAP1
SCHEMBL8286618 0.81 CA12 (0.37) CYP3A4CYP1A2METAP1
SCHEMBL5509358 0.77 CA12 (0.39) GABBR2GABBR1GABRR1CYP3A4CYP1A2
SCHEMBL2951190 0.75 METAP1 (0.49) CYP3A4CYP1A2METAP1
SCHEMBL10901126 0.74 LMNA (0.43) LMNAMETAP1
SCHEMBL5085515 0.74 ADH1B (0.38) CYP3A4CYP1A2METAP1
SCHEMBL2954900 0.74 METAP1 (0.47) CYP3A4CYP1A2METAP1
Hydrochloric Acid SCHEMBL5372871 0.74 METAP1 (0.47) CYP3A4CYP1A2METAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4717276-A2 OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER University of Canberra (AU) 2026-04-01 — — EP claimed
EP-3442516-B1 OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER UNIV CANBERRA (AU) 2025-11-12 — — EP claimed
CN-112770734-B Inhibition method 堪培拉大学 2024-08-20 — — CN claimed
US-11890266-B2 Ophthalmic compositions including levodopa, an antioxidant and an aqueous carrier UNIVERSITY OF CANBERRA (AU) 2024-02-06 — — US claimed
US-20220047529-A1 METHODS OF INHIBITION UNIVERSITY OF CANBERRA (AU) 2022-02-17 — — US claimed
EP-3849533-A1 METHODS OF INHIBITION University of Canberra (AU) 2021-07-21 — — EP claimed
US-20210077443-A1 OPHTHALMIC COMPOSITIONS INCLUDING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER UNIVERSITY OF CANBERRA (AU) 2021-03-18 — — US claimed
US-10874629-B2 Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier UNIVERSITY OF CANBERRA (AU) 2020-12-29 — — US claimed
WO-2020051648-A1 METHODS OF INHIBITION UNIVERSITY OF CANBERRA (AU) 2020-03-19 — — WO claimed
US-20190151270-A1 OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER UNIVERSITY OF CANBERRA (AU) 2019-05-23 — — US claimed
WO-2017177262-A1 OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER UNIVERSITY OF CANBERRA (AU) 2017-10-19 — — WO claimed
EP-1372620-A2 METHODS FOR RESTORING COGNITIVE FUNCTION FOLLOWING SYSTEMIC STRESS Saegis Pharmaceuticals (US) 2004-01-02 — — EP claimed
US-20020187977-A1 Methods for restoring cognitive function following systemic stress SAEGIS PHARMACEUTICALS, INC. 2002-12-12 — — US claimed
WO-2002074293-A2 METHODS FOR RESTORING COGNITIVE FUNCTION FOLLOWING SYSTEMIC STRESS SAEGIS PHARMACEUTICALS INC (US) 2002-09-26 — — WO claimed
US-5545631-A GAMMA-AMINOBUTYRIC ACID ANTAGONIST; TREATS PETIT-MAL TYPE EPILEPSIES CIBA-GEIGY CORPORATION (US) 1996-08-13 — — US claimed
EP-0463560-B1 New antiepileptic agents CIBA GEIGY AG (CH) 1995-10-25 — — EP claimed
EP-0319482-B1 Novel substituted propane phosphinic acid compounds CIBA GEIGY AG (CH) 1994-05-18 — — EP claimed
EP-0463560-A1 New antiepileptic agents CIBA-GEIGY AG (CH) 1992-01-02 — — EP claimed
EP-0319479-A2 Substituted propane-phosphinic acid compounds CIBA-GEIGY AG (CH) 1989-06-07 — — EP claimed
EP-0319482-A2 Novel substituted propane phosphinic acid compounds CIBA-GEIGY AG (CH) 1989-06-07 — — EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020187977-A1 Methods for restoring cognitive function following systemic stress CRH, BDNF, CHAT GABBR2 2093/4885GABBR1 1947/4885GABRR1 420/4885
US-20220047529-A1 METHODS OF INHIBITION SLC6A3, DBH, SNCA GABBR2 943/4885GABBR1 1158/4885GABRR1 248/4885
US-11890266-B2 Ophthalmic compositions including levodopa, an antioxidant and an aqueous carrier TTPA, TST, TXN2 GABBR2 1813/4885GABBR1 1884/4885GABRR1 2709/4885
US-10874629-B2 Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier COMT, LRRK2, PARK7 GABBR2 2730/4885GABBR1 2872/4885GABRR1 1175/4885
US-20190151270-A1 OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER COMT, LRRK2, PARK7 GABBR2 2730/4885GABBR1 2872/4885GABRR1 1175/4885
US-20210077443-A1 OPHTHALMIC COMPOSITIONS INCLUDING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER TTPA, TST, TXN2 GABBR2 1813/4885GABBR1 1884/4885GABRR1 2709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.